

ATL1103/COR-004 - Cortendo NASDAQ IPO Prospectus

Melbourne, Australia, 3 September 2015 - Antisense Therapeutics Limited ("ASX.ANP" or "the Company") wishes to advise that in connection with ANP's licensing partner Cortendo's announcement of filing for US Initial Public Offering on the NASDAQ Global Market, the Form 1 Registration Statement Prospectus is now publically available.

http://www.nasdaq.com/markets/ipos/filing.ashx?filingid=10410903#A2225828ZF-1_HTM_CA18501_PROSPECTUS_SUMMARY

This document contains further information in relation to the ATL1103/COR-004 executed licencing agreement including details with respect to potential milestone payments (refer Exhibit 10.4 for details).

The Company looks forward to providing further updates on progress with the development of ATL1103/COR-004.

Contact Information:

Website: www.antisense.com.au

Managing Director: Mark Diamond +61 (0)3 9827 8999

About Antisense Therapeutics Limited

Antisense Therapeutics Limited is an Australian publicly listed biopharmaceutical drug discovery and development company. Its mission is to create, develop and commercialise second generation antisense pharmaceuticals for large unmet markets. Antisense Therapeutics has 4 products in its development pipeline that it has in-licensed from Isis Pharmaceuticals Inc. (ISIS), a world leader in antisense drug development and commercialisation - ATL1102 (injection) which has successfully completed a Phase II efficacy and safety trial, significantly reducing the number of brain lesions in patients with relapsing-remitting multiple sclerosis (RRMS), ATL1103 drug designed to block GHr production which in a Phase II clinical trial, successfully reduced blood IGF-1 levels in patients with the growth disorder acromegaly, ATL1102 (inhaled) which is at the pre-clinical research stage as a potential treatment for asthma and ATL1101 a second-generation antisense drug at the pre-clinical stage being investigated as a potential treatment for cancer.